Fundz

Abbott Stringham & Lynch

Campbell, Delaware, United States · Biotechnology, Health Care, Manufacturing

Founded in 1977, ASL offers a wealth of experience in delivering high-quality services and specialties to its clients. The firm works with emerging- and middle-market privately held businesses to help them thrive in their markets. ASL also partners with high-net-worth individuals – owners, founders, and executives – to help them protect and grow their wealth. The firm identifies untapped opportuni

Funding history

  • Series senior notes — $20.0B — Feb 2026

Recent signals

  • May 14, 2026: Acquired ASL acquires ArightCo for expanded services
  • Apr 16, 2026: SEC 8-K (2.02): On April 16, 2026, Abbott Laboratories reported its financial results for the first quarter of 2026. The announcement included various non-GAAP financial measures, such as net earnings excluding specified items related to acquisitions and stock-based compensation. The results are provided in their news release, which is attached as Exhibit 99.1. This filing indicates strategic financial adjustments which could impact investors and stakeholders, particularly in light of expenses linked to acquisitions and restructuring actions.
  • Mar 19, 2026: Acquired Abbott to acquire Exact Sciences for diagnostics expansion
  • Mar 09, 2026: SEC 8-K (1.01): On March 9, 2026, Abbott Laboratories entered into a material definitive agreement for the public offering and issuance of senior notes totaling $20,000,000,000 in aggregate principal. This issuance included various tranches: $1,000,000,000 in Floating Rate Notes due 2029, $2,250,000,000 in 3.700% Notes due 2029, $2,500,000,000 in 4.000% Notes due 2031, and $2,750,000,000 in 4.300% Notes due 2033. This significant capital raising effort aims to enhance Abbott's financial position and provide liquidity for corporate purposes, which may include funding ongoing operations and growth initiatives.
  • Feb 28, 2026: Acquired Abbott Laboratories to acquire Exact Sciences
  • Feb 26, 2026: Raised $20.0B in Series senior notes
  • Feb 23, 2026: SEC 8-K (1.01): On February 23, 2026, Abbott Laboratories entered into a Pricing Agreement with underwriters including Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC. As part of this agreement, Abbott will issue and sell $20,000,000,000 in senior notes, which include $1,000,000,000 in Floating Rate Notes due in 2029 and $2,250,000,000 in 3.700% Notes also due in 2029. This financing aims to bolster Abbott's financial position and support its strategic initiatives. The engagement of multiple prominent underwriters signifies strong market confidence in Abbott's upcoming debt issuance.

See plans & pricing → Track Abbott Stringham & Lynch’s funding, hiring, and signals — with verified contacts — on Fundz.